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Mitochondrial isolated complex I deﬁciency is the most frequently encountered OXPHOS defect. We report a patient with an isolated
complex I deﬁciency expressed in skin ﬁbroblasts as well as muscle tissue. Because the parents were consanguineous, we performed ho-
mozygosity mapping to identify homozygous regions containing candidate genes such as NDUFA2 on chromosome 5. Screening of this
gene on genomic DNA revealed a mutation that interferes with correct splicing and results in the skipping of exon 2. Exon skipping was
conﬁrmed on the mRNA level. The mutation in this accessory subunit causes reduced activity and disturbed assembly of complex I. Fur-
thermore, the mutation is associated with a mitochondrial depolarization. The expression and activity of complex I and the depolariza-
tion was (partially) rescued with a baculovirus system expressing the NDUFA2 gene.Introduction
NADH:ubiquinone oxidoreductase, or complex I, is the
ﬁrst and largest complex of the mitochondrial respiratory
chain. Its function is to liberate and transfer electrons
from NADH to ubiquinone and meanwhile to extract
part of their energy to drive proton translocation across
the inner mitochondrial membrane and thus to create an
electrochemical proton gradient that can be used for the
synthesis of ATP. Complex I consists of 45 subunits, of
which seven are encoded by the mitochondrial DNA
(mtDNA). The complex is L-shaped; it has a membrane
arm embedded in the inner mitochondrial membrane
and a peripheral arm protruding into the matrix. Complex
I can be divided into three functional fractions. The ﬂavo-
protein fraction plays a role in FMN and NADH binding,
the iron protein fraction is important in reduction-oxida-
tion reactions via iron-sulfur clusters, and the hydrophobic
protein fraction is involved in proton translocation.
Isolated complex I deﬁciency (MIM 252010) is one of the
most common defects of the OXPHOS system.1 It accounts
for almost 23% of all cases of childhood respiratory-chain
deﬁciency, and the heterogeneous clinical presentation in-
cludes Leigh or Leigh-like syndrome [MIM 256000], cardio-
myopathy, leukodystrophy, and hepatopathy.2,3 Previous
studies identiﬁed disease-causing mutations in eleven
complex I nuclear structural genes (NDUFS1 [MIM
157655], NDUFS2 [MIM 602985], NDUFS3 [MIM 603846],
NDUFS4 [MIM 602694], NDUFS6 [MIM 603848], NDUFS7
[MIM 601825], NDUFS8 [MIM 602141], NDUFV1 [MIM
161015], NDUFV2 [MIM 600532], NDUFA1 [MIM
300078], andNDUFA11).4–14 Most of these genes are evolu-
tionarily highly conserved and play important roles in the
catalytic activity of complex I. Mutations described in
these genes account for only a small part of all complex I1306 The American Journal of Human Genetics 82, 1306–1315, Junedeﬁciencies, suggesting that disease-causing mutations
should be found in other genes such as those encoding
the accessory subunits and assembly factors for complex I.
The latter mutations have been described in the NDUFAF2
(MIM 609653), NDUFAF1 (MIM 606934), and C6orf66
(MIM 611776) genes.15–17
Although for the 14 core subunits of complex I, primary
roles in electron transfer and proton translocation have
been established, the exact role of the remaining 31 acces-
sory subunits is not known yet. It has been suggested that
some are important for the organization of the biogenesis
of complex I. One of the accessory subunits of complex I is
NDUFA2, or bovine B8. This subunit is located in the
peripheral arm of complex I, and analysis of the structure
showed a Fe2S2 ferredoxin fold similar to that found in
thioredoxin.18
In this study we describe a patient whose parents were
consanguineous and in whom isolated complex I deﬁ-
ciency was detected in both muscle tissue and ﬁbroblasts
as a result of a mutation inNDUFA2 (MIM 602137). Homo-
zygosity mapping revealed that the gene NDUFA2 is lo-
cated in a homozygous region on chromosome 5. Screen-
ing of this gene revealed a splice-site mutation resulting
in the skipping of exon 2. With cell biological studies we
demonstrated the pathogenicity of thismutation. Identify-
ing such new disease-causing mutations will deliver new
insights into human complex I deﬁciency.
Material and Methods
Case Report
The patient, a boy, was the second child of consanguineous Turk-
ish parents (ﬁrst cousins). His older sister was healthy. Pregnancy
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cardiomyopathy was diagnosed. Development was retarded from
birth, and at the age of four months, cerebral atrophy and hypo-
plasia of the corpus callosum were seen on MRI. Some weeks later,
atrophy of the N. opticus was diagnosed. At 7.5 months, after a 2
day episode of vomiting and 2 weeks after a varicella infection, the
patient suddenly developed severe acidosis, generalized tonic-
clonic seizures, and coma. The patient did not gain consciousness
again and needed artiﬁcial respiration for 43 days. Afterwards,
respiration was unstable, and the patient had recurrent episodes
of apnea and bradycardia, often accompanied by seizures, which
increased in frequency. Finally, MRI showed demyelinization of
cortico-spinal tracts and subacute necrotizing encephalomyelop-
athy as seen in Leigh syndrome. At eleven months, the patient
died of cardiovascular arrest, after further episodes of apnea and
asystolia.
Cell Culture
Skin ﬁbroblasts were cultured in M199 medium (Life Technolo-
gies) supplemented with 10% fetal calf serum and a combination
of penicillin and streptomycin in a humiﬁed atmosphere of 95%
air and 5% CO2 at 37
C. For live-cell imaging, the ﬁbroblasts
were cultured as described above but in medium 199 with Earle’s
salt supplemented with 10% fetal calf serum and penicillin/
streptomycin.
Biochemical Analysis
Measurement of mitochondrial respiratory-chain enzymes in skin
ﬁbroblasts and in muscle tissue collected at the age of 8 months as
previously described,19,20 with the exception of the Figure 3C
complex I measurements that were performed with a recently
developed assay.21 The values were expressed relative to the activ-
ity of cytochrome c oxidase and/or citrate synthase. The oxidation
rates of pyruvate in the presence of malate or carnitine and the
production rate of ATP from pyruvate were measured in muscle
tissue as described before.22
Homozygosity Mapping
Patient DNA was extracted from cultured ﬁbroblasts by standard
procedures23 and was used for a genome scan with the ABI PRISM
Linkage Mapping Set MD10.A. A total of 382 ﬂuorescently labeled
short tandem repeat (STR) polymorphic markers with an average
heterozygosity of 0.76 were used. The average distance of the
genotyped markers was 10 cM.
Genetic Analysis of the NDUFA2 Gene
Oligonucleotide primers were designed according to public se-
quences (GenBank accession number NM_002488). The exon-
spanning primers F1 (50-CCTTTCCGCTTCCTGTTTTT-30) with R1
(50-GGGGCTTCCCTCAACTTC-30), F2 (50-CTGGGCCTGCGTGAG
ATT-30) with R2 (50-GGGCGGTCCCTTCTCTTCT-30), and F3 (50-
CCATCCAGAATCAGCCAAAA-30) with R3 (50-TCCCACACCT
AAGCCAAGAC-30) were applied in a PCR for ampliﬁcation of
the three exons of the NDUFA2 gene. The exon fragments were
ampliﬁed in a reaction volume of 25 ml containing 100 ng DNA
template, 1 unit of Taq DNA polymerase (Invitrogen), 2.5 ml of
103 PCR buffer, 2.0 mM MgCl2, 50 ng of forward and reverse
primers, 0.25 mM dNTPs, and 0.75 ml DMSO. After an initial dena-
turation step of 2 min at 94C, PCR parameters were 35 cycles for
45 s denaturation at 94C, 45 s annealing at Ta (annealing temper-
ature; 53C for the primers F1/R1 and F3/R3 and 60C for
the primers F2/R2), and 1 min extension at 72C. The cyclesThe Amwere followed by a ﬁnal extension step of 10 min at 72C. The
ampliﬁcation products were run on a 1.5% agarose gel. The
same oligonucleotides were used for direct sequencing with
the BigDye terminator cycle sequencing chemistry on an Applied
Biosystems ABI PRISM 3130xl Genetic Analyzer.
The mutation was also checked on the cDNA level. Patient RNA
was extracted from cultured ﬁbroblasts by standard procedures.
The RNA was reverse transcribed to cDNA by superscript II RNase
H reverse transcriptase with oligo(dT) and random hexamer
primers. The primers F (50-TCGCATCCACTTATGTCAGC-30) and
R (50-GAGGCTTCAGGCTTTACCAC-30) were applied in a PCR as
described above with a Ta of 58C and 1.5 mM MgCl2.
SDS-PAGE and Immunoblot Analysis
Mitochondrial lysates were separated on a 10% SDS-PAGE gel.
Next, the proteins were transferred to PROTAN nitrocellulose
membrane (Schleicher & Schuell) for immunodetection.
BN-PAGE Analysis and in-Gel Activity Assay
Blue native-gradient gels (5%–15%) were cast as described previ-
ously24 and run with 40 or 80 mg of solubilized mitochondrial pro-
tein. After electrophoresis, the gels were further processed for in-
gel activity assay or second-dimension 10% SDS-PAGE followed
by immunoblot analysis as described by Nijtmans et al.24
Antibodies and ECL Detection
Protein immunodetection was performed with primary antibodies
directed against EGFP (a gift fromDr. Frank van Kuppeveld, Nijme-
gen, The Netherlands), NDUFA9 (Invitrogen), the CII 70 kDa
subunit (SDHA; Invitrogen), the CIII CORE2 subunit (UQCRC2;
Invitrogen), and the CIV COXII subunit (COXII; Invitrogen). For
generation of the NDUFA2-speciﬁc antibody, rabbits were immu-
nized with peptide CDQVTRALENVLSGKA that was coupled to
keyhole limpet hemocyanin with the Imject maleimide-activated
mcKLH kit (Pierce). Secondary antibodies used peroxidase-conju-
gated anti-mouse or anti-rabbit IgGs (Invitrogen). The signal was
generated with ECL Plus (Amersham Biosciences).
Generation of Recombinant Baculoviruses
We created the COX8 leader sequence (ﬁrst 210 base pairs of
COX8A, GenBank accession number NM_004074) and NDUFA2
open-reading-frame sequence (without stop codon) ﬂanked by
Gateway ATTB sites (Invitrogen) by PCR and cloned them into
pDONR201 by using the Gateway BP Clonase II enzyme mix
(Invitrogen) to generate the pEntry vectors.25 We made the Bac-
to-Bac system, normally used for protein production in insect
cells, suitable for protein expression in mammalian cells by clon-
ing the vesicular stomatitis virus G protein cDNA behind the
P10 promoter of the pFastBacDual vector. Next, we introduced
the CMV promoter and Gateway destination elements (cassette
that contains the chloramphenicol resistance gene and the ccdB
gene ﬂanked by attR1 and attR2 sites) into this vector.26 Finally,
we cloned the AcGFP1 gene (Clontech) in frame behind the Gate-
way reading-frame cassette to obtain the destination vector pBac-
Dest-GFP. The pEntry vectors were combined with the pBac-Dest-
GFP vector in the Gateway LR reaction to yield the baculovirus
expression vectors. These vectors were used to generate infectious
recombinant baculoviruses by site-speciﬁc transposon-mediated
insertion into a baculovirus genome (bacmid) propagated in
Escherichia coli cells (Bac-to-Bac, Invitrogen). Isolated recombinant
bacmids were used for transfecting Spodoptera frugiperda (Sf9)erican Journal of Human Genetics 82, 1306–1315, June 2008 1307
insect cells, and the viruses were harvested after three passages of
ampliﬁcation.
Transduction of Complex I-Deﬁcient Fibroblasts
with Baculoviral Constructs
Fibroblasts, grown to ~50% conﬂuency in 175 cm2 tissue culture
ﬂasks (NUNC), were transduced with the appropriate baculovirus
in a total volume of 25 ml M199 containing 1.75 mM sodium
butyrate (Sigma-Aldrich). After 24 h at 37C, the virus-containing
medium was discarded and replaced with normal growth medium
containing sodium butyrate. At 3 days after transduction, cells
were harvested for gel electrophoresis or measurement of bio-
chemical complex I activity. Importantly, this transduction proto-
col was developed on the basis of a careful evaluation of different
virus concentrations and different exposure times. We chose the
lowest virus concentration, shortest incubation time, and lowest
butyrate concentration that gave a considerable transduction
(on visual inspection of the GFP signal expressed in ~70% of the
cells) without signs of drastic protein overexpression.
Combined Fluorescence Microscopy of TMRM
and NDUFA2-GFP
For ﬂuorescence imaging of tetramethyl rhodamine methyl ester
(TMRM) and NDUFA2-GFP, ﬁbroblasts, cultured in the above me-
dium containing, in addition, 25 mMHEPES, were seeded on glass
coverslips (diameter 24 mm) and left for 4 hr to attach. Next, cells
were transduced with a baculovirus containing the cDNA of
NDUFA2-GFP for 24 hr (protocol as described above). After trans-
duction, cells were cultured to ~70% conﬂuence in the presence
of 1.75mM sodiumbutyrate for another 48 hr. Immediately before
imaging, cells were loaded with 100 nM TMRM (Invitrogen) for 25
min at 37C. After loading, cells were washed with PBS, and cover-
slips were mounted in a temperature-controlled incubation cham-
ber attached to the stage of an inverted microscope (Axiovert 200
M, Carl Zeiss, Jena, Germany) equipped with a 633, 1.25 NA Plan
NeoFluar objective lens. During image recording, cells were main-
tained in a HEPES-Tris (HT) medium (132 mM NaCl, 4.2 mM KCl,
1 mMMgCl2, 5.5 mM D-glucose, 10 mM HEPES, and 1 mM CaCl2
[pH 7.4]) at 37C. TMRM was excited at 540 nm with an acquisi-
tion and illumination time of 100 ms with a monochromator
(Polychrome IV, TILL Photonics), and ﬂuorescence light was di-
rected by a 560DRLP dichroic mirror (Omega Optical) through
a 565ALP emission ﬁlter (Omega) onto a CoolSNAP HQ mono-
chrome CCD camera (Roper Scientiﬁc Photometrics). NDUFA2-
GFP was excited at 470 nm, and ﬂuorescence light was directed
by a 505DRLPXR dichroic mirror (Omega) through the 565ALP
emission ﬁlter. Importantly, with these settings no bleed-
through of the GFP signal into the TMRM image, and vice versa,
Table 1. Pyruvate Oxidation Rates and ATP Production Rate
from Pyruvate
Oxidation of Patient Control Range
[1-14C]pyruvate þ malate 0.91a 3.61–7.48a
[1-14C]pyruvate þ carnitine 2.19a 2.84–8.24a
ATP þ CrP  production
from pyruvate
8b 42–81b
a nmol CO2/hr $ mU citrate synthase.
b nmol ATP/hr $ mU citrate synthase.1308 The American Journal of Human Genetics 82, 1306–1315, Junwas observed (for details see also reference27). All hardware was
controlled with Metaﬂuor 6.0 software (Molecular Devices
Corporation).
Quantitative Data Analysis
After immunoblotting, the signals were quantiﬁed with Image Pro
Plus 5.1 (Media Cybernetics). The optical density of the bands was
determined and corrected for background. Image analysis after the
combined ﬂuorescence microscopy of TMRM and NDUFA2-GFP
was performed as described previously.27,28 In brief, computer-
assisted processing of the acquired TMRM images produced amito-
chondria-speciﬁc mask. Superimposing this mask on the original
image then allowed quantiﬁcation of the average TMRM ﬂuores-
cence pixel intensity exclusively in the cell’s mitochondrial struc-
tures. We inspected sequences of TMRM and GFP ﬂuorescence in
parallel to select for GFP-positive and -negative cells. Image analy-
sis was performed with Image Pro Plus 5.1. The average value
obtained with the corresponding control cell line (C1) was set at
100%, to which all other values were related. Numerical results
were visualized with Origin Pro 7.5 (Originlabs), and values from
multiple experiments were expressed as means 5 SE (standard
error). Statistical signiﬁcance (Bonferroni corrected) was assessed
with a Student’s t test.
Results
Biochemical and Molecular Genetic Studies
in the Index Patient
Themuscle tissueof the indexpatient clearlydisplayedade-
fect in themitochondrial energy-generating capacity (Table
1). Further investigation of the activities of the enzymes of
the respiratory-chain complex resulted in an isolated com-
plex l deﬁciency, both in muscle tissue and cultured ﬁbro-
blasts. The ﬁbroblast and muscle complex I enzymatic ac-
tivities were 36% and 20% of the lowest control value,
respectively (Table 2). We screened the entire mtDNA and
excluded the presence of disease-causing mutations. We
performed homozygosity mapping to deﬁne genomic re-
gions with candidate genes and found six homozygous re-
gions containing structural subunits of complex I. These
subunits were NDUFS5, NDUFS4, NDUFA2, NDUFA4,
NDUFB6, and NDUFS3. The size of the locus on chromo-
some 5 between the markers D5S2115 and D5S2011 was
6.46 Mb and contained NDUFA2 and probably around 90
other genes. NDUFS4 and NDUFA2 are both located on
Table 2. Respiratory-Chain Enzyme Activities in Skin
Fibroblasts and Muscle Tissue of the Index Patient
Muscle Tissue Skin Fibroblasts
Complex Patient Control Range Patient Control Range
I 14a 70–251a 0.04b 0.11–0.26b
II 78a 67–177a 0.17b 0.07–0.18b
III 2459a 2200–6610a 1.55b 1.27–2.62b
IV 1281a 810–3120a 0.90c 0.68–1.19c
a mU/U citrate synthase.
b mU/mU cytochrome c oxidase.
c mU/mU citrate synthase.e 2008
chromosome 5. Screening of the NDUFS4 gene did not re-
veal a pathogenic mutation. Ampliﬁcation of the three
NDUFA2 exons with exon-spanning primers and sequence
analysis of genomic DNA of the patient demonstrated the
presence of a homozygous G-to-A substitution (c.208þ
5 G > A) after exon 2 (Figure 1A). The mother was found
to be heterozygous for themutation, and themutation was
not found in 107 Turkish controls or 25 patients with iso-
lated complex I deﬁciency who did not harbor a mutation
in the mtDNA. Leigh syndrome was diagnosed in ﬁve of
these patients. We used three different splice-prediction
websites to investigate the possible effect of the mutation
on splicing of the NDUFA2 gene in more detail. The
programs predicted that the mutation would result in
a less efﬁcient splice site, impairing splicing of exon 2.
PCR analysis of the mRNA and subsequent sequencing of
the mutant fragment showed that exon 2 was almost com-
pletelymissing (Figures 1Band1C).A small amountofwild-
type product was present, probably because the splice site
could still be used, but less efﬁciently. The mutation
induced alternative splicing and thereby introduced
a frame-shift resulting in a truncated protein.
Complementation of the Complex I Deﬁciency by
a Baculovirus System Expressing NDUFA2 Protein
To study the effect of the mutation on the expression of
complex I, we performed SDS-PAGE analysis followed by
Figure 1. Genetic Analysis of the Mutation in NDUFA2
(A) Electropherograms showing the normal sequence of
NDUFA2 (top) and the nucleotide change in fibroblasts of the
patient (middle) and the mother of the patient (bottom).
Asterisks represent the nucleotide substitution.
(B) PCR analysis of the mRNA showed a product of approxi-
mately 250 base pairs with control RNA, whereas PCR analysis
with patient RNA resulted in a fragment of about 150 base
pairs. Notably, a small amount of wild-type product was still
present.
(C) Sequence analysis of the PCR fragments of (B) showed a nor-
mal exon boundary between exons 1 and 2 in the control (top)
and skipping of exon 2 in the patient (bottom).
Abbreviations are as follows: wt ¼ wild-type, p ¼ index
patient, M¼mother of patient, C¼ control, and NC¼ negative
control.
immunoblotting with a mitochondria-enriched frac-
tion from cultured patient ﬁbroblasts. Figure 2A shows
amarked decrease in protein level of NDUFA2 in the pa-
tient compared to the control. The immunoblot did not
present the band derived from the mRNA lacking exon
2, probably because the mutant protein is not stable
and will be degraded. Immunodetection with an anti-
body against NDUFA9 also displays a decrease of this
subunit, which suggests a decrease in the amount of
complex I. No increase in CII-SDHA was observed.
These results are in agreement with the biochemical
data. Next, we performed BN-PAGE analysis and in-gel ac-
tivity measurement or immunoblotting to study the effect
of the mutation on the activity and amount of fully
assembled complex I. The in-gel activity (CI-IGA) assay
showed a lower activity of complex I in the patient ﬁbro-
blasts compared to those of the control (Figure 2B). Incuba-
tion with an antibody directed against NDUFA9 resulted in
an extra band when patient ﬁbroblasts were used, which
suggests the formation of catalytically inactive subcom-
plexes. Furthermore, incubation with an antibody against
NDUFA2 demonstrated less NDUFA2, which was only
present in the holo complex I and not in the subcom-
plexes, than in the control. To test whether the assembly
of complex I is disturbed, we performed two-dimensional
BN/SDS-PAGE analysis followed by immunoblotting with
antibodies directed against NDUFS3, NDUFB6, and
NDUFA2 (Figure 2C). The ﬁgure shows the accumulation
of subcomplexes in the patient ﬁbroblasts, and less
NDUFA2 was visible as well. These results indicate a distur-
bance in the assembly and/or stability of complex I.
To conﬁrm the pathogenic role of NDUFA2, we used a
baculovirus expression system containing the NDUFA2
gene in frame with a GFP tag or COX8-GFP as a control.
The viruses were used for the transduction of control ﬁbro-
blasts, ﬁbroblasts of the index patient with a mutation in
NDUFA2, and ﬁbroblasts of an unrelated patient with amu-
tation in the NDUFS7 gene (p.Val122Met).9 The GFP tag
allowed us to distinguish between endogenous andThe American Journal of Human Genetics 82, 1306–1315, June 2008 1309
transduced protein, and this tag did not interfere with the
incorporation of NDUFA2 into complex I (data not
shown). The untreated ﬁbroblasts and the ﬁbroblasts
treated with the baculovirus were used for SDS-PAGE and
BN-PAGE analysis. The SDS-PAGE demonstrated proper ex-
pression of the transduced NDUFA2-GFP fusion protein
(Figure 3A, ﬁrst row). Next, we performed BN-PAGE of
the transduced cells to investigate the expression of com-
plex I. Immunoblot detection with an antibody directed
against NDUFA9 showed almost no difference in the ex-
pression of complex I between the untreated control ﬁbro-
Figure 2. The Mutation in NDUFA2 Results in Lower Expres-
sion and Activity of Complex I and in an Accumulation of
Subcomplexes in the Patient Fibroblasts
(A) SDS-PAGE analysis and immunoblotting with an antibody
directed against NDUFA2 shows that the expression of NDUFA2 is
decreased in the patient fibroblasts. The expression of subunit
NDUFA9 is also reduced, which suggests a reduction in the expres-
sion of complex I.
(B) BN-PAGE analysis followed by an in-gel activity assay shows
decreased complex I activity in the patient with a mutation in
NDUFA2 versus the control. Immunoblotting and incubation with
an antibody directed against NDUFA9 shows a lower expression
of complex I and the formation of an extra band in the fibroblasts
of the patient with the NDUFA2 mutation. The extra band suggests
the formation of a subcomplex. Incubation with an antibody
against NDUFA2 shows less NDUFA2, which is present in the holo
complex I, when patient fibroblasts were used.
(C) Immunoblots of two-dimensional BN/SDS-PAGE show the accu-
mulation of subcomplexes in the patient with the NDUFA2 muta-
tion versus the control. There is also less NDUFA2 detectable in
the patient fibroblasts (third panel).
Abbreviations are as follows: C ¼ control, P-A2 ¼ patient with the
mutation in NDUFA2, (CI)-NDUFA2 ¼ antibody directed against
NDUFA2, (CI)-NDUFA9 ¼ antibody for NDUFA9 to detect whole
complex I, (CII)-SDHA ¼ antibody for SDHA to detect complex
II, (CI)-IGA ¼ in-gel activity of complex I, (CI)-NDUFS3 ¼ anti-
body directed against NDUFS3, and (CI)-NDUFB6 ¼ antibody
directed against NDUFB6.1310 The American Journal of Human Genetics 82, 1306–1315, Junblasts and the cells treated with the baculovirus containing
theNDUFA2 or COX8 construct (Figure 3A, second row). In
contrast, when ﬁbroblasts of the index patient were treated
with the NDUFA2 construct, the expression of complex I
was increased in comparison to expression in untreated
cells and cells treated with the COX8 construct, whereas
ﬁbroblasts of the patient with a mutation in the NDUFS7
gene showed almost no difference in complex I expression
in untreated cells versus cells treated with the constructs.
To check whether the wild-type NDUFA2 subunit was
indeed incorporated, we performed immunoblotting
with the antibody directed against GFP (Figure 3A, third
row). All NDUFA2-GFP was incorporated in complex I in
the ﬁbroblasts of the patient with the NDUFA2 mutation,
whereas in the control and the unrelated patient mono-
meric (unincorporated) NDUFA2-GFP protein could also
be detected (data not shown). The band of GFP attached
to COX8 was visible at the bottom of the gel (data not
shown). Incubation with antibodies for complex II, III,
and IV showed that the assembly of these complexes was
not affected by the NDUFA2 mutation (Figure 3A, rows
four to six). We performed an IGA assay to measure the ac-
tivity of complex I (Figure 3B). Transduction of the control
ﬁbroblasts with baculovirus did not affect the activity of
complex I. The activity of the untreated cells of the index
patient was lower than that of the untreated control cells,
but it was partially rescued in the cells treated with the
baculovirus containing the construct with NDUFA2. Trans-
duction of the baculovirus into the cells of the patient
with a mutation in NDUFS7 did not affect the activity of
complex I. To conﬁrm these observations, we also mea-
sured the activity of complex I by biochemical analysis
(Figure 3C). In the controls cells, the activity of complex
I did not detectably change after treatment with the bacu-
loviruses. However, in the ﬁbroblasts of the patient with
the NDUFA2 mutation, the activity of complex I was
greater in the cells treated with the baculovirus containing
NDUFA2-GFP than in the untreated cells and the cells
treated with the baculovirus with COX8-GFP. No increase
in activity was seen in the ﬁbroblasts of the patient with
theNDUFS7mutation after treatment with the baculovirus
containing NDUFA2-GFP. All of these results together con-
ﬁrm that the complex I deﬁciency expressed in ﬁbroblasts
is complemented by a baculovirus system expressing
NDUFA2.
Mutation in NDUFA2 Is Associated with
Mitochondrial Depolarization in Living Cells, which
Can Be Restored by Baculoviral Complementation
The mitochondrial membrane potential (Dc) is one of the
most important indicators of mitochondrial function and
metabolic activity. It is directly coupled to proper action
of the respiratory chain. Using a recently developed
method to sensitively measure Dc in cultured human
skin ﬁbroblasts,27,28 we here show that the accumulation
of TMRM in the mitochondrial matrix is signiﬁcantly
decreased in ﬁbroblasts of the index patient compared toe 2008
Figure 3. The Decreased Expression and Activity of Complex I
Caused by a Mutation in NDUFA2 Can Be Restored by Baculovi-
ral Complementation
SDS-PAGE and BN-PAGE analysis with immunoblotting of com-
plexes I–IV in control fibroblasts, fibroblasts from the patient
with a mutation in NDUFA2, and fibroblasts from a patient with
a mutation in NDUFS7 confirmed the pathogenicity of the NDUFA2
mutation.
(A) SDS-PAGE analysis followed by immunoblotting confirms
expression of the baculovirus transduced with constructs of
NDUFA2-GFP or with COX8-GFP (top panel). A BN-PAGE gel was blot-
ted and used for immunodetection with an antibody directed
against NDUFA9 to show the expression of complex I. The
untreated control cells and the control cells treated with the bacu-
loviruses show the same expression levels. Expression of complex I
in the fibroblasts of the index patient with a mutation in NDUFA2 is
lower than in the control cells but can be partly rescued if the cells
are treated with the baculovirus. Treating the cells of the patient
with a mutation in NDUFS7 with the baculovirus did not affect
the expression of complex I. In the third panel, detection with
an antibody directed against GFP confirms the incorporation of
the GFP-tagged subunit. COX8-GFP is located in the bottom of
the gel and is not shown. In the next panels, antibodies for com-
plex II, III, and IV showed that the assembly of these complexes
was not affected.The Amfour healthy subjects (Figure 4A). In addition, we demon-
strate that mitochondrial TMRM ﬂuorescence is also
reduced in the ﬁbroblasts of the patient with the NDUFS7
mutation, which suggests that the decrease in Dc is an
important feature of complex I deﬁciency. Although this
reduction appears to be relatively small, it is important to
note that treatment of healthy ﬁbroblasts with 100 nM
rotenone, which caused a marked reduction in complex I
activity,29 decreased the TMRM signal by ~10%.28
Next, we investigated whether baculoviral transduction
of the patient ﬁbroblasts with the NDUFA2-GFP construct
could normalize the observed depolarization of Dc. Here,
we used the advantage of combined measurement of
TMRM and GFP ﬂuorescence, enabling us to assess Dc in
non-transduced (GFP-negative) and transduced (GFP-posi-
tive) cells present on the same coverslip (Figure 4B). The
left image shows that TMRM is virtually exclusively pres-
ent in the mitochondria (red color), whereas the middle
image shows that NDUFA2-GFP ﬂuorescence is most
intense in these organelles but also clearly visible in the
nucleus and cytosol. This image furthermore shows that
the right cell does not detectably express NDUFA2-GFP
and that there was virtually no bleed-through of TMRM
ﬂuorescence during recording of the GFP image. Impor-
tantly, we carefully veriﬁed that there was also no bleed-
through of GFP ﬂuorescence in the TMRM image (for fur-
ther details, see reference27).
As shown in Figure 4C, successful transduction of
healthy ﬁbroblasts (C1, GFP-positive cells) did not alter
the TMRM signal (there was no signiﬁcant difference
(B) In-gel activity assays showed that the activity of complex I
is the same in the untreated and treated control cells transduced
with the baculoviruses. The NDUFA2-mutated patient cells treated
with the baculovirus containing NDUFA2-GFP have higher complex
I activity than the untreated cells and than the cells treated with
the baculovirus containing COX8-GFP. The treatment of the fibro-
blasts of the patient with a NDUFS7 mutation showed a slight in-
crease in the activity of complex I because more protein was loaded
in the last two lanes (see panel CII-SDHA).
(C) Measurement of the activity of complex I by biochemical anal-
ysis showed almost no difference or a slight decrease between the
untreated cells and the control cells treated with the baculovi-
ruses. The fibroblasts of the index patient treated with the baculo-
virus containing NDUFA2-GFP demonstrated an increase in activity
compared to the untreated cells and to the cells treated with the
baculovirus containing COX8-GFP. The treatment of the cells with
the NDUFS7 mutation did not affect the activity of complex I.
Values are given as means 5 standard deviation.
Abbreviations are as follows: C ¼ control, P-A2 ¼ patient with the
mutation in NDUFA2, P-S7 ¼ patient with the mutation p.Val122-
Met in NDUFS7, Untr ¼ untreated fibroblasts, A2 ¼ fibroblasts
treated with the baculovirus containing the NDUFA2 construct,
COX8 ¼ fibroblasts treated with the baculovirus containing the
COX8 construct, (CI)-NDUFA9¼ antibody directed against NDUFA9,
(CI)-GFP ¼ antibody for the GFP-tag, (CII)-SDHA ¼ antibody for
SDHA to detect complex II, (CIII)-CORE2 ¼ antibody for CORE2
to detect complex III, (CIV)-COXII ¼ antibody for COXII to detect
complex IV, and (CI)-IGA ¼ in-gel activity of complex I.erican Journal of Human Genetics 82, 1306–1315, June 2008 1311
Figure 4. Mutation in NDUFA2 in Living Cells Is Associated
with Mitochondrial Depolarization, which Can Be Restored by
Baculoviral Complementation
(A) Average TMRM fluorescence pixel intensity per cell (indicative
of the cell’s mitochondrial membrane potential) of control fibro-
blasts (C1, C2, C3, C4; black bars), of fibroblasts of the patient
with the mutation in NDUFA2 (P-A2 cells; gray bar), and of fibro-
blasts from a patient with a mutation in NDUFS7 (P-S7; gray
bar). Values are given as means5 standard error. The mean value
obtained with the C1 cells was set at 100%, to which all other
values were related. a***, significantly different from C1 cells
(p < 0.001).
(B) Combined imaging of TMRM and NDUFA2-GFP fluorescence in
baculovirus-transduced C1 cells. The left image depicts TMRM fluo-
rescence (red color), the middle image shows the GFP signal of the
same cells (green color), and the right image shows an overlay of
these two images. The yellow color demonstrates colocalization of
TMRM and GFP signal, indicating that only the left cell is trans-
duced. Importantly, no bleed-through from the GFP signal into
the TMRM image was present, and vice versa.
(C) Quantification of the average TMRM pixel fluorescence intensity
in C1, P-A2, and P-S7 cells after transduction with a baculovirus
containing the cDNA of NDUFA2-GFP. After imaging, cells were1312 The American Journal of Human Genetics 82, 1306–1315, Junbetween GFP-negative and GFP-positive cells). On the
other hand, the TMRM signal was fully normalized in
GFP-positive cells of the index patient, whereas the signal
was still signiﬁcantly decreased in their GFP-negative
counterparts. Importantly, no signiﬁcant changes could
be observed for the NDUFS7 patient, demonstrating that
the effect of the NDUFA2 transduction is speciﬁc for the
cells of the index patient. Taken together, these results
convincingly demonstrate that the mutation in the
NDUFA2 gene is responsible for the observed depolariza-
tion of Dc in these patient ﬁbroblasts.
Of note, our GFP measurements revealed that not all
cells were transduced, which might explain why biochem-
ical complex I activity measurements and blue native-gel
electrophoresis followed by either immunoblotting or in-
gel activity measurement did not show full recovery of
complex I amount and activity in the patient ﬁbroblasts.
Discussion
To our knowledge, this is the ﬁrst report describing a muta-
tion in theNDUFA2 gene in a patient with an isolated com-
plex I deﬁciency expressed in skin ﬁbroblasts and muscle
tissue. A mutation in the splice donor site after exon 2
resulted in skipping of that exon and, subsequently, in
a truncated protein of 48 instead of 99 amino acids. Several
lines of evidence suggest that this mutation is the underly-
ing cause of the complex I deﬁciency and, therefore, of the
disease in the patient: (1) the mutation involved a nucleo-
tide change in a conserved region of the 50 splice site,
which is important for correct splicing;30 (2) the mother
was heterozygous for the mutation and the mutation was
not present in 107 controls of the same ethnic background;
(3) the functional consequence of the mutation, skipping
of exon 2, was conﬁrmed at the cDNA level; (4) patient
ﬁbroblasts showed a decrease in complex I amount and ac-
tivity as revealed by immunoblotting and biochemical and
in-gel activity measurements; (5) the assembly of complex
I was disturbed in these cells; (6) the mitochondrial mem-
brane potential, as determined in intact cells, was depolar-
ized in intact patient ﬁbroblasts; and most importantly, (7)
transduction with a baculoviral vector containing the
wild-type NDUFA2 gene speciﬁcally restored both complex
selected according to their GFP signal (GFP-negative, black and
gray bars; GFP-positive, green bars), and for each subgroup, the av-
erage TMRM pixel intensity per cell was calculated. Values are given
as means5 standard error. The mean value obtained with the GFP-
negative C1 cells was set at 100%, to which all other values were
related. a***, significantly different from GFP-negative C1 cells
(p < 0.01); b**, significantly different from GFP-negative P-A2
cells (p < 0.01). Numerals in (A) and (C) represent the number
of individual cells analyzed.
Abbreviations are as follows: C1-4 ¼ control 1-4, P-A2 ¼ patient
with the mutation in NDUFA2, P-S7 ¼ patient with the mutation
p.Val122Met in NDUFS7.e 2008
I amount and activity and mitochondrial membrane
potential in these patient ﬁbroblasts.
Fourteen of the complex I subunits are highly conserved
across species, from mammals to bacteria.31,32 It is as-
sumed that the orthologs of the bacterial subunits form
the minimal functional complex of higher organisms.33
These subunits are essential for the catalysis of electron
transfer from NADH to ubiquinone and for the generation
of the proton gradient. Several mutations have been
described in these subunits, causing complex I deﬁciency.
However, the core subunits are not the only locations of
disease-causing mutations. Mutations have also been
described in genes encoding NDUFS4, NDUFS6, NDUFA1,
and NDUFA11, which belong, together with NDUFA2, to
the accessory subunits.
Not much is yet known about the role of complex I
accessory subunits, but the presence of a disease-causing
mutation in NDUFA2 supports the notion that at least
some of them are crucial for proper complex I function.
With 94% identity among mammals, NDUFA2 is one of
the most conserved accessory subunits.34 The structure of
its bovine ortholog, B8, shows a four-stranded mixed
b sheet with three a helices packed against one side. Its
overall structure is very similar to that of thioredoxins,
which has led to the idea that this subunit might link cel-
lular redox state and complex I assembly and/or activity.18
The data presented in this study show that proper assem-
bly of enzymatic active complex I is indeed impaired in
ﬁbroblasts of the index patient. Our data furthermore
show a parallel decrease in the amount and activity of
the fully assembled complex, suggesting that the mutation
primarily decreases the expression of the fully assembled
complex rather than its intrinsic activity. In addition to
its structure, homology to other proteins might also give
an indication of the function of this accessory subunit.
Gabaldon et al. described a paralogous relationship of
NDUFA2 with the mitochondrial ribosomal proteins L43
and S25,35 which might suggest a possible connection
between complex I and mitochondrial translation.
To asses the cellular consequence of the reduction in
complex I amount and activity in the ﬁbroblasts of the
index patient, we performed live-cell imaging of the mito-
chondrial membrane potential (Dc). Dc is a key indicator
of mitochondrial function and cell viability and is main-
tained by the complexes I to IV of the mitochondrial re-
spiratory chain. The mutation in NDUFA2 caused a small
but signiﬁcant depolarization of Dc in the patient cells;
such a depolarization might inﬂuence the function of
the mitochondria. We also observed that Dc was signiﬁ-
cantly depolarized in a patient cell line with a mutation
in NDUFS7, indicating that this depolarization might be
a hallmark of complex I deﬁciency. Importantly, mito-
chondrial depolarization was restored upon baculoviral
complementation of ﬁbroblasts from the index patient,
whereas the NDUFS7 cell line did not show any improve-
ment upon this treatment. This demonstrates that mito-
chondrial depolarizationwas indeed a speciﬁc consequenceThe Amof the NDUFA2 mutation in the ﬁbroblasts of the index
patient.
Complex I deﬁciency is one of the most frequent defects
of the OXPHOS system.36 At present, the exact cause of the
disease is still unknown in many patients with complex I
deﬁciency. Therapeutic strategies for the often devastating
disorders due to complex I malfunction are hardly avail-
able, and it is therefore of eminent importance to identify
possible genetic causes for prenatal diagnostics and genetic
counseling. Here, we report on a patient who had isolated
complex I deﬁciency and who carried a homozygousmuta-
tion in the nuclear gene encoding the accessory complex I
subunit NDUFA2, and we demonstrate with the use of ba-
culoviral complementation technology that this mutation
is responsible for a disturbed assembly of complex I and
that this disturbed assembly leads to a decrease in the
amount of enzymatic active complex and, at the level
of the intact cell, a reduction in mitochondrial membrane
potential.
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